HIV-infected children living in Central Africa have low persistence of antibodies to vaccines used in the expanded program on immunization

PLoS ONE

Volumn 2, Issue 12, 2007, Pages

  Tejiokem, Mathurin C ^a   Gouandjika, Ionela ^b   Béniguel, Lydie ^b   Zanga, Marie Claire Endegue ^a   Tene, Gilbert ^c   Gody, Jean C ^d   Njamkepo, Elisabeth ^e   Kfutwah, Anfumbom ^a   Penda, Ida ^f   Bilong, Catherine ^a   Rousset, Dominique ^a   Pouillot, Régis ^a   Tangy, Frédéric ^e   Baril, Laurence ^e  

^a CENTRE PASTEUR DU CAMEROUN   (Cameroon)

^b INSTITUT PASTEUR DE BANGUI   (Central African Republic)

^c Mother and Child Centre of The Chantal Biya Foundation Yaounde   (Cameroon)

^d Laboratoire des Entérovirus ^*  (South Africa)

^e INSTITUT PASTEUR   (France)

^f Hopital Laquintinie   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; ANTIRETROVIRUS AGENT; DIPHTHERIA ANTIBODY; DIPHTHERIA PERTUSSIS TETANUS VACCINE; LAMIVUDINE; MEASLES ANTIBODY; MEASLES VACCINE; NEVIRAPINE; ORAL POLIOMYELITIS VACCINE; PERTUSSIS ANTIBODY; POLIOMYELITIS VIRUS ANTIBODY; STAVUDINE; TETANUS ANTIBODY; ZIDOVUDINE; BACTERIAL VACCINE; BACTERIUM ANTIBODY; VIRUS ANTIBODY; VIRUS VACCINE;

ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CENTRAL AFRICA; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNIZATION; INFECTION CONTROL; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRESCHOOL CHILD; SEROTYPE; SINGLE DRUG DOSE; AFRICA; BLOOD; CASE CONTROL STUDY; CHILD; IMMUNOLOGY; INFANT;

AFRICA, CENTRAL; ANTIBODIES, BACTERIAL; ANTIBODIES, VIRAL; BACTERIAL VACCINES; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; HIV INFECTIONS; HUMANS; INFANT; VIRAL VACCINES;

EID: 43449116375     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0001260     Document Type: Article

References (44)

1. WHO/UNAIDS, Report on the global AIDS epidemic (2006) Available: http://www.unaids.org/en/HIV_data/2006GlobalReport via the Internet. Accessed 15 Sept 2007.
2. WHO. Immunization service delivery and accderated disease control. Vaccine Preventable Diseases. World Health Organization (Last update April 2006). Available: http://www.who.int/immunization_delivery/ vaccines via the Internet. Accessed 15 Sept 2007.
3. Moss WJ, Clements CJ, Halsey NA (2003) Immunization of children at risk of infection with human immunodeficiency virus. Bull World Health Organ 81: 61-70.
4. Pancharoen C, Ananworanich J, Thisyakorn U (2004) Immunization for persons infected with human immunodeficiency virus. Curr HIV Res 2: 293-299.
5. Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, et al. (2005) Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting. J Clin Microbiol 43: 2709-2717.
6. Scott S, Cumberland P, Shulman CE, Cousens S, Cohen BJ, et al. (2005) Neonatal measles immunity in rural Kenya: the influence of HIV and placental malaria infections on placental transfer of antibodies and levels of antibody in maternal and cord serum samples. J Infect Dis 191: 1854-1860.
7. Cohen BJ, Parry RP, Doblas D, Samuel D, Wartener L, et al. (2006) Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Methods 131: 209-212.
8. Relyveld E, Oato NH, Guerin N, Coursaget P, Huet M, et al. (1991) Determination of circulating antibodies directed to pertussis toxin and of agglutinogens in children vaccinated with either the whole cell or component pertussis vaccine in France, Japan and Senegal. Vaccine 9: 843-850.
9. WHO (1997) Neutralisation test for polio antibodies In: Manual for the virological investigation of poliovirus (Chapter 6). pp 44-49 .
10. WHO. Antiretroviral therapy of HIV infection in infants and children in resource-limited settings: recommendations for a public health approach. Availabl:e http://www.who.int/hiv/pub/guidelines/VVHOpaediatric.pdf via he Internat. Accessed 15 Sept 2007.
11. Dunn D, HIV Paedianic Prognostic Markers Collaborative Study Group (2003) Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 362: 1605-1611.
12. de Onis M, Yip R, Mei Z (1997) The development of MUAC-for-age reference data recommended by a WHO Expert Conuoittee. Bull World Health Organ 75: 11-18.
13. Setse RW, Cutts F, Monze M, Ryon JJ, Quinn TC, et al. (2006) HIV-1 Infection as a risk factor for incomplete childhood immunization in Zambia. J Trop Pediatr 52: 324-328.
14. Helfand RF, Moss WJ, Harpaz R, Scott S, Cutts F (2005) Evaluating the impact of the HIV pandemic on measles control and elimination. Bull World Health Organ 83: 329-337.
15. Wolfson LJ, Strebel PM, Gacic-Dobo M, Hoekstra EJ, McFarland JW, et al. (2007) Has the 2005 measles mortality reduction goal been achieved? A natural history modelling study. Lancet 369: 191-200.
16. Rudy BJ, Rutstein RM, Pinto-Martin J (1994) Responses to measles immunization in children infected with human immunodeficiency virus. J Pediatr 125: 72-74.
17. Arpadi SM, Markowitz LE, Baughman AL, Shah K, Adam H, et al. (1996) Measles antibody in vaccinated human inummodeficiency virus type 1-infected children. Pediatrics 97: 653-657.
18. Lindgren-Alves CR, Freire LM, Oliveira RC, Guerra HL, Da-Silva EE, et al. (2001) Search of antimeasles antibodies in HIV-infectcd children after basic immunization. J Pediatr (Rio J) 77: 496-502.
19. Lepage P, Dabis F, Msellati P, Hitimana DG, Stevens AM, et al. (1992) Safety and immumogenicity of high-dose Edmonston-Zagreb measles vaccine in children with HIV-1 infection. A cohort study in Kigali, Rwanda. Am J Dis Child 146: 550-555.
20. Garenne M, Leroy O, Beau JP, Sene I (1991) Child mortality after high-titre measles vaccines: prospective study in Senegal, Lancet 338: 903-907.
21. Waibale P, Bowlin SJ, Mortimer EA Jr, Whalen C (1999) The effect of human immunodeficiency virus-1 infection and stunting on measles inummoglobulin-G levels in children vaccinated against measles in Uganda. Int J Epidemiol 28: 341-346.
22. Grais RF, Dubray C, Gerstl S, Guthmann JP, Djibo A, et al. (2007) Unacceptably high mortality related to measles epidemics in Niger, Nigeria, and Chad. PLoS Med 4. e16. Available: http://medicine.plosjournals.org via the Internet Accessed 17 Sept 2007.
23. Moss WJ (2007) Measles still has a devastating impact in unvaccinated populations. PLoS Med 2007 4: e24. Available: http://medicine.plosjournals. org via the Internet. Accessed 17 Sept 2007.
24. Bautista-Lopez N, Ward BJ, Mills E, McCormick D, Martel N, et al. (2000) Development and durability of measles antigen-specific lymphoproliferative response after MMR vaccination. Vaccine 18: 1393-1401.
25. Gans H, Yasukawa L, Rinki M, DeHovitz R, Forghani B, et al. (2001) Immune responses to measles and mumps vaccination of infants at 6, 9, and 12 months. J Infect Dis 184: 817-826.
26. Naniche D, Garenne M, Rae C, Manchester M, Buchta R, et al. (2004) Decrease in measles virus-specific CD4 T cell memory in vaccinated subjects. J Infect Dis 190: 1387-1395.
27. Al-Attar I, Reisman J, Muehlmann M, McIntosh K (1995) Decline of measles antibody titers after immunization in human immunodeficiency virus-infected children. Pediatr Infect Dis J 14: 149-151.
28. Brunell PA, Vimal V, Sandir M, Courville TM, Daar E, et al. (1995) Abnormalities of measles antibody response in human immunodeficiency virus type 1 (RIV- 1) infection. J Acquir Immune Defic Syndr Hum Retrovirol. 10: 540-548.
29. Bekker V, Scherpbier H, Pajkrt D, Jurriaans S, Zaarier H, et al. (2006) Persistent humoral immune defect in highly active antirctroviral therapy-treated children with HIV-1 infection: loss of specific antibodies against attenuated vaccine strains and natural viral infection. Pediatries 118: 315-322.
30. Newell ML, Coovadia H, Cortina-Borja M, Rollins N, Gaillard P, et al. (2004) Mortality of infected and uninfected infants born to HIV-infected mothers in Africa: a pooled analysis. Lancet 364: 1236-1243.
31. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ (2006) Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 212: 289-295.
32. Brenchley JM, Price DA, Douek DC (2006) HIV disease: fallout from a mucosal catastrophe? Nat Immunol 7: 235-239.
33. Lepage P, Msellati P, Hitimana DG, Bazubagira A, Van Goethem C, et al. (1996) Growth of human immunodeficiency type 1-infected and uninfected children: a prospective cohort study in Kigali, Rwanda, 1988 to 1993. Pediatr Infect Dis J 15: 479-485.
34. Taha TE, Graham SM, Kumwenda NI, Broadhead RL, Hoover DR, et al. (2000) Morbidity among human immunodeficiency virus-1-infected and - uninfected African children. Pediatrics 106: E77.
35. McNally LM, Jeena PM, Gajec K, Thula SA, Sturm AW, et al. (2007) Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children. a prospective descriptive study. Lancet 369: 1440-1451.
36. Clerici M, Saresella M, Colombo F, Fossati S, Sala N, et al. (2000) T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV. Blood 96: 3866-3871.
37. Vigano A, Saresella M, Schenal M, Erba P, Piacentini L, et al. (2007) Immune activation and normal levels of endogenous antivirals are seen in healthy adolescents born of HIV-infected mothers. AIDS 21: 245-248.
38. Barbi M, Biffi MR, Binda S, Clerici-Schoeller M, Ferraris G, et al. (1992) Immunization in children with HIV seropositivity at birth: antibody response to polio vaccine and tetanus toxoid. AIDS 6: 1465-1469.
39. Ryder RW, Oxtoby MJ, Mvula M, Batter V, Baende E, et al. (1993) Safety and immunogenicity of bacille Calmette-Guerin, diphtheria-tetanus-pertussis, and oral polio vaccines in newborn children in Zaire infected with human immunodeficiency virus type 1. J Pediatr 122: 697-702.
40. Sutter RW, Suleiman AJ, Malankar P, Al-Khusaiby S, Mehta F, et al. (2000) Trial of a supplemental dose of four poliovirus vaccines. N Engl J Med 343: 767-773.
41. Triki H, Abdallah MV, Ben Aissa R, Bourathine A, Ben Ali Kacem M, et al. (1997) Influence of host related factors on the antibody response to trivalent oral polio vaccine in Tunisian infants. Vaccine 15: 1123-1129.
42. Fassinou P, Elenga N, Rouet F, Laguide R, Kouakoussui KA, et al. (2004) Highly active antiretroviral therapies among HIV-1-infected children in Abidjan, Cote d'Ivoire. AIDS 18: 1905-1913.
43. Faye A, Le Chenadec J, Dollfus C, Tburet I, Douard D, et al. (2004) Early versus deferred antiretroviral mulhdrug therapy in infants infected with HIV type 1. Clin Infect Dis 39: 1692-1698.
44. Chiappini E, Galli L, Tovo PA, Gabiano C, Gattinara GC, et al. (2006) Virologic, immunologic, and clinical benefits from early combined antiretroviral therapy in infants with perinatal HIV-1 infection. AIDS 20: 207-215.